Superhydrophobicity from the Inside

The nature of trapped air on submersed ultra-water-repellent interfaces has been investigated. These gaseous layers (plastrons) can last from hours to, in some examples such as the <i>Salvinia molesta</i> fern, months. The interface of submerged superhydrophobic surfaces with carefully controlled micropatterned surface roughness has been probed using synchrotron-based high-resolution X-ray phase tomography. This technique looks in situ, through the aqueous/gas interface in three dimensions. Long-term plastron stability appears to correlate with the appearance of scattered microdroplets <20 μm in diameter that are sandwiched within the 30 μm thick gaseous interfacial layer. These microdroplets are centered on defects or damaged sections within the substrate surface approximately 20–50 μm apart. Such irregularities represent heterogeneous micro/nano-hierarchical structures with varying surface structures and chemistry. The stability of microdroplets is governed by a combination of electrostatic repulsion, contact angle limitations, and a saturated vapor pressure, the latter of which reduces the rate of diffusion of gas out of the air layer, thus increasing underwater longevity. Homogenous surfaces exhibiting purely nano- or micro-regularity do not support such microdroplets, and, as a consequence, plastrons can disappear in <20 h compared with >160 h for surfaces with scattered microdroplets. Such behavior may be a requirement for long-term nonwetting in any system

Toward second-generation cardiomyogenic and anti-cardiofibrotic 1,4-dihydropyridine-class TGFβ inhibitors

Innovative therapeutic modalities for pharmacological intervention of transforming growth factor β (TGFβ)-dependent diseases are of great value. b-Annelated 1,4-dihydropyridines (DHPs) might be such a class, as they induce TGFβ receptor type II degradation. However, intrinsic drawbacks are associated with this compound class and were systematically addressed in the presented study. It was possible to install polar functionalities and bioisosteric moieties at distinct sites of the molecules while maintaining TGFβ-inhibitory activities. The introduction of a 2-amino group or 7-N-alkyl modification proved to be successful strategies. Aqueous solubility was improved by up to seven-fold at pH 7.4 and 200-fold at pH 3 relative to the parent ethyl 4-(biphenyl-4-yl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate. The therapeutic potential of the presented DHPs was further underscored in view of a potential dual mode of action: The differentiation of committed human iPSC-derived cardiac progenitor cells (CPCs) was potently stimulated, and the rescue of cardiac fibrosis phenotypes was observed in engineered heart tissue (EHT) constructs

From local to European low emission freight concepts: Summary report 3 - LowCarb-RFC - European Rail Freight Corridors Going Carbon Neutral

This third and final summary report of the study LowCarb-RFC turns the attention on low carbon emission scenarios from the European perspective to the German region of North Rhine-Westphalia (NRW). For NRW we developed and assessed specific rail modal shift and road electrification scenarios towards 2050. To achieve profound cuts in GHG emissions we find that planning periods need significant shortening, and system transition has to start immediately. In particular, new technologies to boost rail capacity are needed as shifting all rail freight to electric trucks would require inconceivable road network expansions. Total investment costs between 2015 and 2050 range between 15 billion euros for a lower bound rail investment case to 19 billion euros for motorway electrification and expansion. None of these costs create major disruptions to the NRW economy or labour market and thus do not constitute an excuse for not acting. The NRW case study finds lower GHG reduction potentials, −16 per cent, than the European corridors studies (−28 to −43 per cent) for the railway expansion and modal shift scenarios. For road electrification all cases find a potential of some −60 per cent. Interestingly, also for GHG mitigation costs NRW values are lower in the Pro Rail case (140 euros per ton CO2-eq.) than in the corridor studies (around 600 euros per ton CO2-eq.). Environmental and safety external costs suggest that GHG mitigation shall be prioritised. For profound and fast decarbonisation, all options are needed, including CO2-efficient shipping

Feasibility of randomizing Danish citizens aged 65-79 years to high-dose quadrivalent influenza vaccine vs. standard-dose quadrivalent influenza vaccine in a pragmatic registry-based setting:rationale and design of the DANFLU-1 Trial

BACKGROUND: High-dose influenza vaccines provide better protection against influenza infection than standard-dose in persons aged 65 years and above; however, in most countries, high-dose vaccines are not widely implemented. Assessing the relative effectiveness of high-dose compared to standard-dose vaccines on hospitalizations and mortality would enable more robust public health and cost-effectiveness estimates. This study aims to investigate the feasibility of conducting a pragmatic randomized clinical trial in Denmark comparing high-dose to standard-dose vaccines utilizing existing vaccination infrastructure and the Danish nationwide health registries for data collection. METHODS: The DANFLU-1 trial (NCT05048589) is a pragmatic, open-label, active-controlled randomized trial randomizing Danish citizens aged 65–79 years to either high-dose quadrivalent influenza vaccine or standard-dose quadrivalent influenza vaccine. The study utilizes the infrastructure of a private vaccination provider (Danske Lægers Vaccinations Service) for recruitment, inclusion, randomization, and vaccination. All collection of baseline and follow-up data including safety monitoring is performed centrally by the Department of Cardiology at Herlev and Gentofte Hospital, Copenhagen, Denmark using the Danish nationwide health registries. The study aims to include 40,000 participants during the 2021/2022 influenza season. The primary endpoints address feasibility and include the number of participants enrolled, randomization balance, and representativeness compared to the Danish general population. Relative vaccine effectiveness will also be assessed, however, this feasibility study is not powered for clinical outcomes and may be affected by the COVID-19 pandemic. DISCUSSION: The DANFLU-1 study is investigating the feasibility of conducting a large-scale pragmatic clinical trial in Denmark utilizing existing infrastructure and the Danish nationwide registries. This will provide valuable insight, especially for potential future fully powered vaccine trials, but also for trials wishing to investigate other interventions. TRIAL REGISTRATION: Clinicaltrials.gov: NCT05048589, registered September 17, 2021

A pragmatic randomized feasibility trial of influenza vaccines

Background The relative vaccine effectiveness (rVE) of high-dose quadrivalent influenza vaccines (QIV-HD) versus standard-dose quadrivalent influenza vaccines (QIV-SD) against hospitalizations and mortality in the general older population has not been evaluated in an individually randomized trial. Because of the large sample size required, such a trial will need to incorporate innovative, pragmatic elements. Methods We conducted a pragmatic, open-label, active-controlled, randomized feasibility trial in Danish citizens aged 65 to 79 years during the 2021–2022 influenza season. Participants were randomly assigned 1:1 to receive QIV-HD or QIV-SD. Randomization was integrated into routine vaccination practice, and the trial relied solely on nationwide administrative health registries for data collection. Outcomes consisted of a feasibility assessment and descriptive rVE estimates. Results We invited 34,000 persons to participate. A total of 12,477 randomly assigned participants were included in the final analyses. Mean (±SD) age was 71.7±3.9 years, and 5877 (47.1%) were women. Registry-based data collection was feasible, with complete follow-up data for 99.9% of participants. Baseline characteristics were comparable to those of the overall Danish population aged 65 to 79 years. The incidence of hospitalization for influenza or pneumonia was 10 (0.2%) of 6245 in the QIV-HD group and 28 (0.4%) of 6232 in the QIV-SD group (rVE, 64.4%; 95% confidence interval, 24.4 to 84.6). All-cause death occurred in 21 (0.3%) and 41 (0.7%) participants in the QIV-HD and QIV-SD groups, respectively (rVE, 48.9%; 95% confidence interval, 11.5 to 71.3). Conclusions Conducting a pragmatic randomized trial of QIV-HD versus QIV-SD using existing infrastructure and registry-based data collection was feasible. The findings of lower incidence of hospitalization for influenza or pneumonia and all-cause mortality in the QIV-HD group compared with the QIV-SD group require replication in a future, fully powered trial. (Funded by Sanofi; ClinicalTrials.gov number, NCT05048589.

Levodopa Dose Equivalency in Parkinson's Disease : Updated Systematic Review and Proposals

Background: To compare drug regimens across clinical trials in Parkinson's disease (PD) conversion formulae between antiparkinsonian drugs have been developed. These are reported in relation to levodopa as the benchmark drug in PD pharmacotherapy as ‘levodopa equivalent dose’ (LED). Currently, the LED conversion formulae proposed in 2010 by Tomlinson et al. based on a systematic review are predominantly used. However, new drugs with established and novel mechanisms of action and novel formulations of longstanding drugs have been developed since 2010. Therefore, consensus proposals for updated LED conversion formulae are needed. Objectives: To update LED conversion formulae based on a systematic review. Methods: The MEDLINE, CENTRAL, and Embase databases were searched from January 2010 to July 2021. Additionally, in a standardized process according to the GRADE grid method, consensus proposals were issued for drugs with scarce data on levodopa dose equivalency. Results: The systematic database search yielded 3076 articles of which 682 were eligible for inclusion in the systematic review. Based on these data and the standardized consensus process, we present proposals for LED conversion formulae for a wide range of drugs that are currently available for the pharmacotherapy of PD or are expected to be introduced soon. Conclusions: The LED conversion formulae issued in this Position Paper will serve as a research tool to compare the equivalence of antiparkinsonian medication across PD study cohorts and facilitate research on the clinical efficacy of pharmacological and surgical treatments as well as other non-pharmacological interventions in PD